Melvin Sharoky Biography and Net Worth

Director of Insmed

Dr. Sharoky has been a member of our board since May 2001 and served as chairman of our board from June 2009 to December 2010. Since January 2008, Dr. Sharoky has been retired. From 2007 to 2012, he was a member of the board of directors of Par Pharmaceutical Companies, Inc., a publicly traded pharmaceutical manufacturer, which was subsequently acquired by Endo International plc (Nasdaq: ENDP). From 2002 to 2007, Dr. Sharoky was President and Chief Executive Officer of Somerset Pharmaceuticals, Inc. Dr. Sharoky continued as a consultant to Somerset until 2007. From 2001 to 2002, Dr. Sharoky was retired. From July 1995 to June 2001, Dr. Sharoky served as President of Somerset Pharmaceuticals. From 1995 through 1998, Dr. Sharoky was President of Watson Pharmaceuticals, Inc. (acquired by Actavis plc), and from 1993 to 1998 he was President and Chief Executive Officer of Watson’s wholly owned subsidiary, Circa Pharmaceuticals, Inc. From 1988 to 1993, Dr. Sharoky held various senior executive positions with Circa Pharmaceuticals. From 1986 to 1988, Dr. Sharoky was Vice President and Chief Medical Officer of Pharmakinetics Laboratories, Inc. Dr. Sharoky holds a Bachelor of Arts degree in biology from the University of Maryland in Baltimore County and a Doctor of Medicine degree from the University of Maryland School of Medicine. Dr. Sharoky is a member of the Nominations & Governance Committee and the Science & Technology Committee.

What is Melvin Sharoky's net worth?: The estimated net worth of Melvin Sharoky is at least $19.84 million as of October 31st, 2022. Dr. Sharoky owns 281,021 shares of Insmed stock worth more than $19,837,272 as of December 24th. This net worth evaluation does not reflect any other assets that Dr. Sharoky may own. Learn More about Melvin Sharoky's net worth.
How do I contact Melvin Sharoky?: The corporate mailing address for Dr. Sharoky and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on Melvin Sharoky's contact information.
Has Melvin Sharoky been buying or selling shares of Insmed?: Melvin Sharoky has not been actively trading shares of Insmed within the last three months. Most recently, on Monday, October 31st, Melvin Md Sharoky bought 20,000 shares of Insmed stock. The stock was acquired at an average cost of $17.53 per share, with a total value of $350,600.00. Following the completion of the transaction, the director now directly owns 281,021 shares of the company's stock, valued at $4,926,298.13. Learn More on Melvin Sharoky's trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Sara Bonstein (CFO), David Brennan (Director), Martina Flammer (Insider), William Lewis (CEO), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 492,966 shares worth more than $23,747,841.53. The most recent insider tranaction occured on December, 19th when CEO William Lewis sold 18,750 shares worth more than $1,310,812.50. Insiders at Insmed own 4.6% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 12/19/2024.

Melvin Sharoky Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/31/2022	Buy	20,000	$17.53	$350,600.00	281,021
5/11/2022	Buy	20,000	$17.20	$344,000.00	262,621
9/15/2020	Sell	20,000	$30.68	$613,600.00	236,890
11/12/2018	Buy	8,795	$15.59	$137,114.05	231,794
11/9/2018	Buy	11,205	$16.34	$183,089.70	231,794
9/6/2017	Sell	50,000	$27.37	$1,368,500.00
8/13/2014	Buy	88,889	$11.25	$1,000,001.25

Melvin Sharoky Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $70.50

$69.81

$70.82

50 Day Range

MA: $72.27

$66.29

$76.65

2 Week Range

Now: $70.50

$21.92

$80.53

Volume

97,100 shs

Average Volume

2,203,977 shs

Market Capitalization

$12.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment

From Behind the Markets | Ad

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>